Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42,815 real-world patients with inflammatory rheumatic disease
In this medfyle
Introduction and switching of bDMARDs are associated with the presence of mood disorders.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the RMD Open, EULAR’s official journal, through an official agreement with BMJ.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Rene Westhovens, MD, PhD, Rheumatologist, Emeritus Professor KU Leuven, Belgium.
Original article:
Bournia V, Tektonidou MG, Vassilopoulos D, et al. Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. RMD Open 2020;6:e001303. doi: 10.1136/rmdopen-2020-001303.
The authors of the original article had no part in the creation of the summary.
Copyright © 2020 BMJ Publishing Group Limited and Globalport (International) Limited. All rights reserved.
The summaries, expert commentaries and slides included in this Medfyle are co-owned by BMJ and GlobalPort (International) Limited. The original journal article is an exclusive copyright of BMJ Publishing Group Limited.
